Trial Outcomes & Findings for Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients (NCT NCT03348683)
NCT ID: NCT03348683
Last Updated: 2020-01-07
Results Overview
The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.
COMPLETED
PHASE2
240 participants
average of 24 hours
2020-01-07
Participant Flow
First enrollment 12-11-2017, final enrollment 12/11/2018. Enrollment occurred on the labor floor of the Mount Sinai Hospital.
Participant milestones
| Measure |
Propranolol
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Overall Study
STARTED
|
121
|
119
|
|
Overall Study
COMPLETED
|
121
|
119
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients
Baseline characteristics by cohort
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
Total
n=240 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
31.70 years
STANDARD_DEVIATION 5.72 • n=99 Participants
|
31.61 years
STANDARD_DEVIATION 6.37 • n=107 Participants
|
31.66 years
STANDARD_DEVIATION 6.04 • n=206 Participants
|
|
Sex: Female, Male
Female
|
121 Participants
n=99 Participants
|
119 Participants
n=107 Participants
|
240 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
16 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
21 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
16 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
72 Participants
n=99 Participants
|
83 Participants
n=107 Participants
|
155 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
17 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
37 Participants
n=206 Participants
|
|
Body Mass Index (BMI) at admission
|
29.04 kg/m^2
STANDARD_DEVIATION 5.34 • n=99 Participants
|
28.89 kg/m^2
STANDARD_DEVIATION 4.40 • n=107 Participants
|
28.97 kg/m^2
STANDARD_DEVIATION 4.89 • n=206 Participants
|
|
Gestational Age (GA) at admission
|
39.7 months
n=99 Participants
|
40.1 months
n=107 Participants
|
40.0 months
n=206 Participants
|
|
Married
|
94 Participants
n=99 Participants
|
97 Participants
n=107 Participants
|
191 Participants
n=206 Participants
|
|
Private Insurance
|
101 Participants
n=99 Participants
|
93 Participants
n=107 Participants
|
194 Participants
n=206 Participants
|
|
In vitro Fertilization (IVF)
|
18 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
37 Participants
n=206 Participants
|
|
Fetal Growth Restriction
|
8 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Tobacco Use
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: average of 24 hoursPopulation: N=154 - only those who delivered vaginally
The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.
Outcome measures
| Measure |
Propranolol
n=75 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=79 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Time From Beginning of Induction to Delivery
|
13.8 hours
Standard Deviation 5.4
|
14.3 hours
Standard Deviation 5.3
|
SECONDARY outcome
Timeframe: average of 24 hoursNumber of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Participants With Various Mode of Delivery
Spontaneous vaginal delivery
|
64 Participants
|
61 Participants
|
|
Number of Participants With Various Mode of Delivery
Vacuum assisted vaginal delivery
|
3 Participants
|
10 Participants
|
|
Number of Participants With Various Mode of Delivery
Forceps assisted vaginal delivery
|
8 Participants
|
8 Participants
|
|
Number of Participants With Various Mode of Delivery
Cesarean section
|
46 Participants
|
40 Participants
|
SECONDARY outcome
Timeframe: average of 24 hoursTime of latent labor defined as \<6cm of cervical dilation.
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Duration of Latent
|
11.0 hours
Standard Deviation 5.0
|
11.2 hours
Standard Deviation 4.5
|
SECONDARY outcome
Timeframe: average of 24 hoursComposite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission. The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Participants With Maternal Morbidity Composite Score = 1
|
35 Participants
|
49 Participants
|
SECONDARY outcome
Timeframe: 30 minutes from drug administrationGreater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Participants With Postpartum Hemorrhage
|
15 Participants
|
26 Participants
|
SECONDARY outcome
Timeframe: 30 minutes from drug administrationCount of fetus with fetal heart rate decelerations within 30 minutes of study drug administration
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Fetus With Heart Rate Decelerations
|
15 Participants
|
13 Participants
|
SECONDARY outcome
Timeframe: 30 minutes from drug administrationCount of fetus with fetal bradycardia (\<110bpm for \>10 minutes within 30 minutes of study drug administration)
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Fetus With Fetal Bradycardia
|
1 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Day 1Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death. The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.
Outcome measures
| Measure |
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Neonates With Neonatal Outcome Composite Score = 1
|
21 Participants
|
28 Participants
|
SECONDARY outcome
Timeframe: Day 1Population: This population includes the neonates who had heelsticks to check their blood glucose.
Neonatal outcome - Number of neonates with hypoglycemia (blood glucose \<50). This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)
Outcome measures
| Measure |
Propranolol
n=45 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=49 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Number of Neonates With Hypoglycemia
|
11 Participants
|
8 Participants
|
Adverse Events
Propranolol
Placebo
Serious adverse events
| Measure |
Propranolol
n=121 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Pregnancy, puerperium and perinatal conditions
Fetal bradycardia
|
0.83%
1/121 • 24 hours
|
0.00%
0/119 • 24 hours
|
Other adverse events
| Measure |
Propranolol
n=121 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
|
Placebo
n=119 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
|
|---|---|---|
|
Vascular disorders
Maternal hypotension
|
0.83%
1/121 • 24 hours
|
0.00%
0/119 • 24 hours
|
|
Pregnancy, puerperium and perinatal conditions
Fetal heart rate decelerations
|
12.4%
15/121 • 24 hours
|
10.9%
13/119 • 24 hours
|
Additional Information
Dr. Catherine A Bigelow
Icahn School of Medicine at Mount Sinai
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place